Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Harringtonine is a natural alkaloid isolated from plants of the genus Cephalotaxus, particularly Cephalotaxus harringtonia. It acts as a protein synthesis inhibitor by blocking the initiation of polypeptide synthesis in eukaryotic cells. Specifically, it immobilizes ribosomes after translation initiation by inhibiting peptide bond formation and aminoacyl-tRNA binding at the ribosomal A site[1][3][4]. This mechanism leads to potent antitumor activity and apoptosis induction in rapidly dividing cells. Harringtonine has demonstrated antiviral properties against several viruses including influenza and chikungunya virus[1]. It has been investigated for use in hematological malignancies such as acute myeloid leukemia, myelodysplastic syndromes, Philadelphia chromosome positive chronic myelogenous leukemia, and polycythemia vera[5]. Common side effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and fatigue[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on harringtonine.